Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
Type:
Application
Filed:
June 15, 2016
Publication date:
June 21, 2018
Applicants:
MERCK PATENT GMBH, PFIZER INC.
Inventors:
Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON
Abstract: The present invention provides a method for generating bispecific shark variable antibody domains (vNAR domains) and uses thereof. The present invention further provides fusion proteins comprising the inventive bispecific vNAR domains as well as polynucleotide libraries for use in the generation of the inventive bi-specific vNARs. Furthermore, the invention provides pharmaceutical compositions comprising the inventive bispecific vNARs or fusion proteins comprising bi-specific vNAR domains for use in the treatment of pathological conditions in an individual. The invention also provides kits of parts comprising the bispecific vNAR domains or fusion proteins.
Type:
Application
Filed:
October 21, 2015
Publication date:
June 21, 2018
Applicant:
Merck Patent GmbH
Inventors:
Stefan Becker, Bjoern Hock, Stefan Zielonka, Harald Kolmar, Martin Empting
Abstract: The invention relates to the compounds of the formula I and to a liquid-crystalline medium based on a mixture of polar compounds which contains at least one compound of the formula I in which in which R1, R2, ring A1, Z1, Z2, Sp, P, L1, L2, r1, r2, r3, m, n, p1 and p2 have the meanings indicated in Claim 1 and to the use of the LC mixtures in electro-optical displays, especially for the self-aligning VA, PSA, PS-VA, PVA, MVA, PM-VA, HT-VA or VA-IPS mode.
Type:
Application
Filed:
September 8, 2016
Publication date:
June 21, 2018
Applicant:
Merck Patent GmbH
Inventors:
Graziano ARCHETTI, Elena NEUMANN, Rocco FORTTE, Timo UEBEL, Helmut HAENSEL, Kristin MUELLER
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Inventors:
Ying YU, Andrew Evan DENKER, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, David Ross KAUFMAN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
Abstract: Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.
Type:
Application
Filed:
February 13, 2018
Publication date:
June 21, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Joseph TERRACCIANO, Nicole Miller DAMOUR, Chun JIANG, Giovanni FOGLIATO, Giuseppe Alessandro DONADELLI, DARIO RESEMINI
Abstract: The present invention relates to crystal modifications of racemic (2R,S)- and enantiomerically pure (2R)-resp. (2S)-DOTAP chloride, to processes for the preparation thereof, and to the use thereof for the preparation of pharmaceutical compositions.
Type:
Grant
Filed:
May 2, 2012
Date of Patent:
June 19, 2018
Assignee:
MERCK PATENT GMBH
Inventors:
Michael Wilhelm Platscher, Alfred Hedinger
Abstract: The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
Type:
Grant
Filed:
November 20, 2015
Date of Patent:
June 19, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Scott D. Kuduk, Thomas S. Reger, Jason W. Skudlarek
Abstract: The invention relates to co-activated magnesium alumosilicate based phosphors, to a process of its preparation, the use of these phosphors in electronic and electro optical devices, such as light emitting diodes (LEDs) and solar cells and especially to illumination units comprising said magnesium alumosilicate-based phosphors.
Abstract: The invention relates to compounds which can be used in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
Type:
Grant
Filed:
December 18, 2014
Date of Patent:
June 19, 2018
Assignee:
Merck Patent GmbH
Inventors:
Amir Hossain Parham, Thomas Eberle, Anja Jatsch, Christof Pflumm, Jonas V. Kroeber
Abstract: The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
Type:
Grant
Filed:
December 16, 2014
Date of Patent:
June 19, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Harry Chobanian, Barbara Pio, Yan Guo, Fa-Xiang Ding, Shuzhi Dong, Shawn P. Walsh, Jinlong Jiang, Dooseop Kim
Abstract: The present invention relates to the field of anti-counterfeit protection of products. Specifically, the invention is directed to a composite security marking for a physical object, in particular to an anti-counterfeit product marking. In particular, without limitation, such composite security marking can be used in connection with or can form a component of a multi-component security system, in particular of an anti-counterfeit protection system, which is also disclosed herein as part of an overall solution for anti-counterfeit protection. The composite security marking comprises a physical unclonable function, PUF, and a representation of a digital signature or of a pointer indicating a location where said digital signature can be accessed. The digital signature digitally signs a hash value resulting from application of a predetermined cryptographic hash function to data representing a response generated by the PUF in reaction to a challenge of a predetermined challenge-response authentication scheme.
Type:
Grant
Filed:
February 9, 2017
Date of Patent:
June 19, 2018
Assignee:
Merck Patent GmbH
Inventors:
Thomas Endress, Daniel Szabo, Fabian Wahl
Abstract: This disclosure relates to salt forms of ceftolozane, processes for making these salt forms, and compositions comprising the same. Also disclosed are stabilized compositions of ceftolozane. Provided herein are salt forms of ceftolozane, processes for making these salt forms and compositions comprising the same. The salt forms provided herein include ceftolozane bromide, ceftolozane edisylate, ceftolozane mesylate, ceftolozane chloride, ceftolozane sulfate, ceftolozane maleate, ceftolozane phosphate, and ceftolozane ketoglutarate.
Type:
Grant
Filed:
August 17, 2015
Date of Patent:
June 19, 2018
Assignee:
MERCK SHARP & DOHME CORP.
Inventors:
Jian-Qiao Gu, Valdas Jurkauskas, Carlos Lopez, Kristos Adrian Moshos, Pradip M. Pathare, Sudhakar Garad, You Seok Hwang
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Type:
Grant
Filed:
May 19, 2015
Date of Patent:
June 19, 2018
Assignee:
Merck Sharp & Dohme
Inventors:
Tesfaye Biftu, Purakkattle Biju, Timothy A. Blizzard, Zhengxia Chen, Matthew J. Clements, Mingxiang Cui, Jessica L. Frie, William K. Hagmann, Bin Hu, Hubert Josien, Anilkumar G. Nair, Christopher W. Plummer, Cheng Zhu
Abstract: The present invention relates to the field of anti-counterfeit protection of products. Specifically, the invention is directed to a method of reading with a reader device a marking comprising a physical unclonable function, PUF, and a corresponding reader device. In particular, such reader device marking can be used in connection with or can form a component of a multi-component security system, in particular of an anti-counterfeit protection system, which is also disclosed herein as part of an overall security solution for anti-counterfeit protection.
Type:
Grant
Filed:
February 9, 2017
Date of Patent:
June 19, 2018
Assignee:
Merck Patent GmbH
Inventors:
Thomas Endress, Daniel Szabo, Fabian Wahl
Abstract: The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Type:
Grant
Filed:
September 23, 2015
Date of Patent:
June 19, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Jiaqiang Cai, Vincent Colandrea, Alejandro Crespo, John Debenham, Xiaoxing Du, Deodialsingh Guiadeen, Ping Liu, Rongqiang Liu, Christina B. Madsen-Duggan, Joshua G. McCoy, Weiguo Quan, Christopher Sinz, Liping Wang
Abstract: The present invention relates to an organic composition which comprises a conjugated polymer as hole-transport compound and a doping compound. The present invention furthermore relates to the use of the composition according to the invention in organic electroluminescent devices, in particular in the so-called buffer layer of such devices. The present invention also relates to a formulation which comprises the composition according to the invention and a solvent and to an organic electroluminescent device which comprises the composition according to the invention.
Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.
Type:
Application
Filed:
August 3, 2016
Publication date:
June 14, 2018
Applicant:
Merck Patent GmbH
Inventors:
Lars DOBELMANN-MARA, Stefan RIEDMUELLER, Martin SCHRAUB
Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Type:
Application
Filed:
June 20, 2016
Publication date:
June 14, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Gregori J. Morriello, Michael P. Dwyer, Lehua Chang, Yili Chen, Ming Wang, Ashley Forster, Richard Berger, Kausik k Nanda, Jaime L Bunda, William D Shipe